© Reuters.
SANTA CLARA, Calif. – HeartBeam, Inc. (NASDAQ:BEAT), a company specializing in cardiac care medical technology, announced that it has received two new patents from the United States Patent and Trademark Office. These additions bring the company's portfolio to 14 US and 4 international patents for its vector electrocardiography (VECG) technology. This technology captures three-dimensional signals from the heart and translates them into 12-lead electrocardiograms (ECG).
The newly patented VECG technology is designed for use with compact, easy-to-handle devices such as a credit card-sized system, stretchable wearables, or wristwatches. These devices are designed to allow doctors to remotely monitor patients' heart health.
One of the patents, “Mobile Three-Lead Cardiac Monitoring Device and Method for Automatic Diagnosis,” is for automatic detection of myocardial infarction or acute myocardial infarction (AMI) by comparing cardiac signals over time.
HeartBeam's approach is to provide each patient with a comparative baseline ECG, which helps clinicians gain detailed information about the patient's heart health. This method was validated by a study published in JACC: Advances, which demonstrated a significant improvement in diagnostic accuracy using the HeartBeam VECG method compared to traditional 12-lead ECG.
The second patent, „Electrocardiogram Generating Apparatus,” refers to Hartbeam's wrist-based ECG system. This is the second patent for the company's watch concept, which is designed to continuously monitor the ECG and provide a highly sensitive 12-lead ECG from a wrist-worn device.
In addition to these patents, HeartBeam has 20 patent applications pending worldwide. The patents and applications cover fundamental aspects of HeartBeam's VECG technology and include wearable devices, continuous monitors, extended-wear connections and clock-based 12-lead ECGs.
The information in this article is copyright of HeartBeam, Inc
This article was developed and translated with support from AI and reviewed by one editor. For more information, see our T&Cs.
